- Home
- CCJ vs ILMN Comparison
CCJ vs ILMN Comparison
Compare CCJ & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCJ
- ILMN
- Stock Information
- Founded
- CCJ 1987
- ILMN 1998
- Country
- CCJ Canada
- ILMN United States
- Employees
- CCJ N/A
- ILMN N/A
- Industry
- CCJ Other Metals and Minerals
- ILMN Medical Specialities
- Sector
- CCJ Basic Materials
- ILMN Health Care
- Exchange
- CCJ Nasdaq
- ILMN Nasdaq
- Market Cap
- CCJ 23.6B
- ILMN 23.6B
- IPO Year
- CCJ N/A
- ILMN 2000
- Fundamental
- Price
- CCJ $52.62
- ILMN $135.21
- Analyst Decision
- CCJ Strong Buy
- ILMN Buy
- Analyst Count
- CCJ 4
- ILMN 17
- Target Price
- CCJ $66.56
- ILMN $163.12
- AVG Volume (30 Days)
- CCJ 3.4M
- ILMN 2.3M
- Earning Date
- CCJ 02-20-2025
- ILMN 02-06-2025
- Dividend Yield
- CCJ 0.22%
- ILMN N/A
- EPS Growth
- CCJ N/A
- ILMN N/A
- EPS
- CCJ 0.19
- ILMN N/A
- Revenue
- CCJ $2,069,888,595.00
- ILMN $4,390,000,000.00
- Revenue This Year
- CCJ $17.28
- ILMN N/A
- Revenue Next Year
- CCJ $8.80
- ILMN $4.05
- P/E Ratio
- CCJ $265.40
- ILMN N/A
- Revenue Growth
- CCJ 23.31
- ILMN N/A
- 52 Week Low
- CCJ $35.43
- ILMN $97.36
- 52 Week High
- CCJ $62.55
- ILMN $156.66
- Technical
- Relative Strength Index (RSI)
- CCJ 40.70
- ILMN 40.42
- Support Level
- CCJ $51.60
- ILMN $130.31
- Resistance Level
- CCJ $53.43
- ILMN $137.69
- Average True Range (ATR)
- CCJ 2.01
- ILMN 5.31
- MACD
- CCJ -0.72
- ILMN -1.10
- Stochastic Oscillator
- CCJ 9.32
- ILMN 22.85
About CCJ Cameco Corporation
Cameco Corp is a provider of uranium needed to generate clean, reliable baseload electricity around the globe. one of those uranium producers. Cameco has three reportable segments, uranium, fuel services and Westinghouse. It derives maximum revenue from Uranium Segment. It has some projects namely; Millennium, Yeelirrie, Kintyre and Exploration. The company operates in Canada, Kazakhstan, Germany, Australia and United States.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.